2021 was a landmark year for ExSeed, and 2022 is already shaping up to be even more transformative. We’re excited to announce that we have closed an additional £2.5 million ($3.4m) investment round, bringing our total seed-stage funding to more than £5 million ($6.8m). This milestone strengthens our mission to revolutionise male fertility testing worldwide.
A Significant Vote of Confidence in Male Fertility Innovation
The round was led by the Ascension Life Fund, with participation from Trifork, Hambro Perks, R42 Group, and several forward-thinking organisations and angel investors who believe in our mission to improve the diagnosis and treatment of male fertility issues.
“ExSeed has an exciting technology that addresses a real need in the fertility market, and they have established strong partnerships with leading pharmaceutical companies in the fertility space,” says Özgür Tuncer, Partner at Ascension Life Fund.
“They have a strong team and proven science, and we are delighted to support their journey.”
Building on Our Incredible Growth
This investment comes at a time when ExSeed is already experiencing remarkable momentum. Last year alone, our growth increased fourfold, and more than 15,000 sperm tests were completed through the ExSeed app.
“This funding round is critically important for us and our mission to improve the treatment paradigm for male infertility and tackle the social stigma that often surrounds it,” explains our Co-Founder and CEO, Morten G. Ulsted.
“It will help us reach more people who need support and accelerate the research and development required to bring new, advanced products to market. By enabling men to test, and potentially improve, their fertility at home, ExSeed is helping to break taboos and raise awareness around male reproductive health.”
We are also seeing increasing opportunities to collaborate with healthcare providers across Europe and globally, including the NHS and leading private fertility clinics. For many patients, an ExSeed test is becoming the first step on their wider fertility journey.
A Global Challenge That Requires New Solutions
Male fertility continues to be one of the most urgent and overlooked health issues affecting men worldwide. In the UK alone, infertility affects 3.5 million people, and sperm counts have fallen by almost 50% over the past four decades.
Our at-home sperm test offers a simple and comfortable way to assess sperm health either before visiting a clinic or alongside ongoing fertility treatment. With a growing network of clinical partners, our solution is empowering more men to take control of their reproductive health.
Game-Changing Technology and an Incredible Community
Our innovative sperm test combines the advanced camera technology of modern smartphones with sophisticated cloud-based analysis. You can provide a sample from the privacy of your home and view a live video of your sperm directly on your screen. Within minutes, you receive an accurate quantitative assessment of sperm concentration and motility.
ExSeed also provides personalised lifestyle recommendations and access to fertility experts for anyone who needs additional guidance.
But it’s not just our technology that’s making an impact.
“Our investment in ExSeed demonstrates our confidence in the future of health tech,” says Dominic Perks, Co-founder and CEO of Hambro Perks. “Male infertility is a growing global problem that remains largely taboo. We hope ExSeed’s mission will transform the lives of millions of couples who struggle to conceive each year.”
Driving Positive Change in Male Fertility Awareness
We’re proud to be part of a rapidly growing community that is working to break the stigma around male infertility. We believe that combining cutting-edge technology with open, supportive conversation is the key to helping more men and couples access better care and achieve stronger reproductive outcomes.
If fatherhood is in your near future, we’d love to support you with the knowledge and tools to maximise your chances.
You can learn more about the ExSeed at-home sperm test right here.
